Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO committee tells...

    CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug

    Farhat NasimWritten by Farhat Nasim Published On 2019-10-27T11:30:11+05:30  |  Updated On 16 Aug 2021 11:16 AM IST

    New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO), recently recommended drugmaker, Roche to submit Phase III clinical trial data of Polatuzumab Vedotin, a blood cancer drug for which the firm had sought to waiver.


    Roche presented its proposal for permission to import and marketing of the drug for the indication "Polatuzumab Vedotin in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large B-Cell lymphoma (DLBCL) who are not candidate for hematopoietic stem cell transplant" with the waiver of Phase III and Phase IV clinical trial in the country.


    In 2017, Roche had announced that the drug, in a mid-stage trial had shown a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone.


    Also Read: Roche lymphoma drug drives high remission rate, longer survival: study


    The CDSCO committee recently noted that the drug has been approved by USFDA through accelerated approval process based on Phase II study on a limited number of patients for the indication in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. As per USFDA approval, the firm is required to conduct two Phase III studies.


    The CDSCO committee opined that although the proposed indication is a rare disease, considering the safety profile of the drug (GradeIII/IV toxicities of 84.6%), Phase III clinical trial data is required for further consideration. The committee also noted that efficacy data has been generated in the Phase II study with relatively weak comparator arm.


    Therefore, the CDSCO committee recommended that the firm should submit Phase III clinical trial data of the drug.


    Also Read: Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC

    bendamustineCDSCOCentral Drug Standard Control OrganisationClinical Triallymphomapharmapharma newspharma news india Committeephase 3 trialRituximabRocheSEC CommitteeSubject ExpertUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok